Swedish University Hospital investigates a Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery

Sahlgrenska University Hospital, Sweden is starting a new clinical trial of Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery.

The study aims to test whether platelet transfusion or fibrinogen concentrate is the most effective treatment of intraoperative bleeding, when performing open heart surgery with cardiopulmonary bypass on children with congenital heart defects.

The clinical trial started in March 14, 2018 and will continue throughout August 2022.

The inclusion parameters:

  • Children < 1 years of age, scheduled for open surgery of congenital heart defects, using cardiopulmonary bypass.
  • Body weight < 10 kg.
  • Expected CPB time > 90 minutes.

The contacts and locations are the Sahlgrenska University Hospital, Gothenburg, Sweden.

The Sahlgrenska University Hospital Sahlgrenska Universitetssjukhuset) is a system of hospitals associated with the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. With 17,000 employees the hospital is the largest hospital in Sweden by a considerable margin, and the second largest hospital in Europe. It provides emergency and basic care for the 700,000 inhabitants of the Göteborg region and offers highly specialised care for the 1.7 million inhabitants of West Sweden. It is named after philanthropist Niclas Sahlgren.

For more details: https://ichgcp.net/clinical-trials-registry/NCT04807621

Clinical Research News

Próximos ensaios clínicos